Showing 312 results
October 2021
-
Media ReleaseNovartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of SandozAd hoc announcement pursuant to Art. 53 LR Q3 net sales grew +5% (cc¹, +6% USD) Innovative Medicines grew +7% (cc, +8% USD) Strong performance of key growth drivers: Entresto (+44% cc), Cosentyx…
-
Media ReleaseNovartis signs new initial agreement with BioNTech to support fill and finish of the mRNA Pfizer-BioNTech COVID-19 vaccineAt least 24 million doses of the mRNA-based vaccine will be filled in 2022 into vials under sterile conditions at Novartis Technical Operations state-of-the-art facility in Ljubljana, Slovenia New…
-
Media ReleaseSandoz completes acquisition of GSK’s cephalosporin business, reinforcing leading global position in antibioticsSandoz gains rights to three established brands sold in more than 100 markets Transaction, including leading global brand Zinnat®, complements Sandoz leadership in generic penicillins with leading…
-
Media ReleaseSandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic DrugsCompany previously disclosed settlement agreement in principle and fully provisioned for this resolution Basel, October 1, 2021 – Sandoz Inc., the U.S. subsidiary of Sandoz, has entered a settlement…
July 2021
-
Media ReleaseNovartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged.Ad hoc announcement pursuant to Art. 53 LR Net sales in Q2 grew +9% (cc¹, +14% USD): Pharmaceuticals BU grew +12% (cc, +18% USD) with continued strong growth from Entresto (+46% cc), Cosentyx (+21…
-
Media ReleaseSandoz launches first generic high dose intravenous iron, Ferumoxytol Injection, to treat US patients with iron deficiency anemiaPatients with iron deficiency anemia in a hospital or clinic setting now have access to an important IV iron medicine at a more affordable price Iron deficiency anemia occurs when there is a lower…
May 2021
-
Media ReleaseSandoz announces plans to further strengthen its antibiotics manufacturing setup in EuropeSandoz to invest €150 million in new antibiotics manufacturing technology in Europe over next three to five years, to be optimally prepared for future needs Kundl, Austria further strengthens…
-
Media ReleaseUS Supreme Court denies Sandoz petition to review biosimilar Erelzi® (etanercept-szzs) caseDecision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of more affordable Erelzi treatment option for US patients Sandoz is disappointed US patients affected by…
-
Media ReleaseSandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicineSandoz to begin enrolling patients with neovascular age-related macular degeneration in MYLIGHT Phase lll confirmatory efficacy and safety study1 Neovascular age-related macular degeneration…